COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study.
Journal
The Lancet. Rheumatology
ISSN: 2665-9913
Titre abrégé: Lancet Rheumatol
Pays: England
ID NLM: 101765308
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
31
8
2020
medline:
31
8
2020
entrez:
1
9
2020
Statut:
ppublish
Résumé
A subset of patients with severe COVID-19 develop a hyperinflammatory syndrome, which might contribute to morbidity and mortality. This study explores a specific phenotype of COVID-19-associated hyperinflammation (COV-HI), and its associations with escalation of respiratory support and survival. In this retrospective cohort study, we enrolled consecutive inpatients (aged ≥18 years) admitted to University College London Hospitals and Newcastle upon Tyne Hospitals in the UK with PCR-confirmed COVID-19 during the first wave of community-acquired infection. Demographic data, laboratory tests, and clinical status were recorded from the day of admission until death or discharge, with a minimum follow-up time of 28 days. We defined COV-HI as a C-reactive protein concentration greater than 150 mg/L or doubling within 24 h from greater than 50 mg/L, or a ferritin concentration greater than 1500 μg/L. Respiratory support was categorised as oxygen only, non-invasive ventilation, and intubation. Initial and repeated measures of hyperinflammation were evaluated in relation to the next-day risk of death or need for escalation of respiratory support (as a combined endpoint), using a multi-level logistic regression model. We included 269 patients admitted to one of the study hospitals between March 1 and March 31, 2020, among whom 178 (66%) were eligible for escalation of respiratory support and 91 (34%) patients were not eligible. Of the whole cohort, 90 (33%) patients met the COV-HI criteria at admission. Despite having a younger median age and lower median Charlson Comorbidity Index scores, a higher proportion of patients with COV-HI on admission died during follow-up (36 [40%] of 90 patients) compared with the patients without COV-HI on admission (46 [26%] of 179). Among the 178 patients who were eligible for full respiratory support, 65 (37%) met the definition for COV-HI at admission, and 67 (74%) of the 90 patients whose respiratory care was escalated met the criteria by the day of escalation. Meeting the COV-HI criteria was significantly associated with the risk of next-day escalation of respiratory support or death (hazard ratio 2·24 [95% CI 1·62-2·87]) after adjustment for age, sex, and comorbidity. Associations between elevated inflammatory markers, escalation of respiratory support, and survival in people with COVID-19 indicate the existence of a high-risk inflammatory phenotype. COV-HI might be useful to stratify patient groups in trial design. None.
Sections du résumé
BACKGROUND
BACKGROUND
A subset of patients with severe COVID-19 develop a hyperinflammatory syndrome, which might contribute to morbidity and mortality. This study explores a specific phenotype of COVID-19-associated hyperinflammation (COV-HI), and its associations with escalation of respiratory support and survival.
METHODS
METHODS
In this retrospective cohort study, we enrolled consecutive inpatients (aged ≥18 years) admitted to University College London Hospitals and Newcastle upon Tyne Hospitals in the UK with PCR-confirmed COVID-19 during the first wave of community-acquired infection. Demographic data, laboratory tests, and clinical status were recorded from the day of admission until death or discharge, with a minimum follow-up time of 28 days. We defined COV-HI as a C-reactive protein concentration greater than 150 mg/L or doubling within 24 h from greater than 50 mg/L, or a ferritin concentration greater than 1500 μg/L. Respiratory support was categorised as oxygen only, non-invasive ventilation, and intubation. Initial and repeated measures of hyperinflammation were evaluated in relation to the next-day risk of death or need for escalation of respiratory support (as a combined endpoint), using a multi-level logistic regression model.
FINDINGS
RESULTS
We included 269 patients admitted to one of the study hospitals between March 1 and March 31, 2020, among whom 178 (66%) were eligible for escalation of respiratory support and 91 (34%) patients were not eligible. Of the whole cohort, 90 (33%) patients met the COV-HI criteria at admission. Despite having a younger median age and lower median Charlson Comorbidity Index scores, a higher proportion of patients with COV-HI on admission died during follow-up (36 [40%] of 90 patients) compared with the patients without COV-HI on admission (46 [26%] of 179). Among the 178 patients who were eligible for full respiratory support, 65 (37%) met the definition for COV-HI at admission, and 67 (74%) of the 90 patients whose respiratory care was escalated met the criteria by the day of escalation. Meeting the COV-HI criteria was significantly associated with the risk of next-day escalation of respiratory support or death (hazard ratio 2·24 [95% CI 1·62-2·87]) after adjustment for age, sex, and comorbidity.
INTERPRETATION
CONCLUSIONS
Associations between elevated inflammatory markers, escalation of respiratory support, and survival in people with COVID-19 indicate the existence of a high-risk inflammatory phenotype. COV-HI might be useful to stratify patient groups in trial design.
FUNDING
BACKGROUND
None.
Identifiants
pubmed: 32864628
doi: 10.1016/S2665-9913(20)30275-7
pii: S2665-9913(20)30275-7
pmc: PMC7442426
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e594-e602Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211153/Z/18/Z
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 22203
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.
Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Infect Dis. 2020 May 02;:
pubmed: 32358954
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Br J Haematol. 2020 Jul;190(1):e9-e11
pubmed: 32369612
BMC Med. 2017 Sep 18;15(1):172
pubmed: 28918754
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Rheumatology (Oxford). 2019 Jan 1;58(1):5-17
pubmed: 29481673
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Infect Dis. 2020 Jun;20(6):635-636
pubmed: 32224308
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet Rheumatol. 2020 Jul;2(7):e379-e381
pubmed: 32835233
BMC Pulm Med. 2015 Mar 14;15:22
pubmed: 25888398
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Nat Commun. 2020 Jul 15;11(1):3543
pubmed: 32669540
J Rheumatol. 2020 May 1;47(5):639-642
pubmed: 32209661
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Arthritis Rheumatol. 2017 Jun;69(6):1135-1143
pubmed: 28217930
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
Thorax. 2017 Oct;72(10):876-883
pubmed: 28450529
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Emerg Microbes Infect. 2020 Dec;9(1):1230-1232
pubmed: 32515651
Blood Rev. 2020 May 15;:100707
pubmed: 32425294
Chest. 2009 Aug;136(2):471-480
pubmed: 19411291
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454